Anti–IL-33 clinical trials are currently ongoing in patients with asthma, food allergy, chronic rhinosinusitis, chronic obstructive and airways disease, and an anti-ST2 is under investigation in patients with chronic obstructive airways disease (for further details, see http://clinicaltrials.gov/). Here, IL1RL1 is linked to asthma.